Progression of Alport Kidney Disease in Col4a3 knock out mice is independent of sex or macrophage depletion by clodronate treatment

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Kim, Munkyung ^a   Piaia, Alessandro ^a   Shenoy, Neeta ^b   Kagan, David ^b   Gapp, Berangere ^a   Kueng, Benjamin ^a   Weber, Delphine ^a   Dietrich, William ^b   Ksiazek, Iwona ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; KIDNEY INJURY MOLECULE 1; LIPOSOME; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; AUTOANTIGEN; COLLAGEN TYPE 4; TYPE IV COLLAGEN ALPHA3 CHAIN;

ALPORT SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CELL INFILTRATION; COL4A3 GENE; CONTROLLED STUDY; DEPLETION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY TUBULE DAMAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; SEX DIFFERENCE; 129 MOUSE; ANIMAL; APOPTOSIS; DEFICIENCY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KIDNEY; KIDNEY FAILURE, CHRONIC; KNOCKOUT MOUSE; NEPHRITIS, HEREDITARY; PATHOLOGY; PATHOPHYSIOLOGY; PRECLINICAL STUDY; SEXUAL DEVELOPMENT;

ANIMALS; APOPTOSIS; AUTOANTIGENS; CLODRONIC ACID; COLLAGEN TYPE IV; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; FEMALE; KIDNEY; KIDNEY FAILURE, CHRONIC; LIPOSOMES; MACROPHAGES; MALE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; MODELS, ANIMAL; NEPHRITIS, HEREDITARY; SEX CHARACTERISTICS;

EID: 84953317924     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141231     Document Type: Article

References (43)

1. Hasstedt SJ, Atkin CL (1983) X-linked inheritance of Alport syndrome: family P revisited. Am J Hum Genet 35: 1241-1251.
2. Hertz JM, Thomassen M, Storey H, Flinter F (2012) Clinical utility gene card for: Alport syndrome. Eur J Hum Genet 20.
3. Flinter F (1997) Alport's syndrome. J Med Genet 34: 326-330.
4. Kruegel J, Rubel D, Gross O (2013) Alport syndrome-insights from basic and clinical research. Nat Rev Nephrol 9: 170-178. doi: 10.1038/nrneph.2012.259
5. Korstanje R, Caputo CR, Doty RA, Cook SA, Bronson RT, et al. (2014) A mouse Col4a4 mutation causing Alport glomerulosclerosis with abnormal collagen alpha3alpha4alpha5(IV) trimers. Kidney Int 85: 1461-1468. doi: 10.1038/ki.2013.493
6. Cosgrove D, Meehan DT, Grunkemeyer JA, Kornak JM, Sayers R, et al. (1996) Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome. Genes Dev 10: 2981-2992.
7. Miner JH, Sanes JR (1996) Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol 135: 1403-1413.
8. Rheault MN, Kren SM, Thielen BK, Mesa HA, Crosson JT, et al. (2004) Mouse model of X-linked Alport syndrome. J Am Soc Nephrol 15: 1466-1474.
9. Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, et al. (2003) Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63: 438-446.
10. Gross O, Licht C, Anders HJ, Hoppe B, Beck B, et al. (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81: 494-501. doi: 10.1038/ki.2011.407
11. Temme J, Peters F, Lange K, Pirson Y, Heidet L, et al. (2012) Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 81: 779-783. doi: 10.1038/ki.2011.452
12. Mochizuki T, Lemmink HH, Mariyama M, Antignac C, Gubler MC, et al. (1994) Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 8: 77-81.
13. Kalluri R, Cosgrove D (2000) Assembly of type IV collagen. Insights from alpha3(IV) collagen-deficient mice. J Biol Chem 275: 12719-12724.
14. Whalen RE, Huang S, Peschel E, Mc IH (1961) Hereditary nephropathy, deafness and renal foam cells. Am J Med 31: 171-186.
15. Rodgers KD, Rao V, Meehan DT, Fager N, Gotwals P, et al. (2003) Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis. Kidney Int 63: 1338-1355.
16. Dennis J, Meehan DT, Delimont D, Zallocchi M, Perry GA, et al. (2010) Collagen XIII induced in vascular endothelium mediates alpha1beta1 integrin-dependent transmigration of monocytes in renal fibrosis. Am J Pathol 177: 2527-2540. doi: 10.2353/ajpath.2010.100017
17. Ninichuk V, Gross O, Reichel C, Khandoga A, Pawar RD, et al. (2005) Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol 16: 977-985.
18. Clauss S, Gross O, Kulkarni O, Avila-Ferrufino A, Radomska E, et al. (2009) Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deficient mice with autosomal recessive Alport nephropathy. J Pathol 218: 40-47. doi: 10. 1002/path.2505
19. van Rooijen N, Sanders A, van den Berg TK (1996) Apoptosis of macrophages induced by liposomemediated intracellular delivery of clodronate and propamidine. J Immunol Methods 193: 93-99.
20. Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93.
21. Kitamoto K, Machida Y, Uchida J, Izumi Y, Shiota M, et al. (2009) Effects of Liposome Clodronate on Renal Leukocyte Populations and Renal Fibrosis in Murine Obstructive Nephropathy. Journal of Pharmacological Sciences 111: 285-292.
22. Jo SK, Sung SA, Cho WY, Go KJ, Kim HK (2006) Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol Dial Transplant 21: 1231-1239.
23. Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, et al. (2011) Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle 2: 9-25.
24. Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, et al. (2012) Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 27: 38-46. doi: 10.1002/jbmr.516
25. Sampson NS, Ryan ST, Enke DA, Cosgrove D, Koteliansky V, et al. (2001) Global gene expression analysis reveals a role for the alpha 1 integrin in renal pathogenesis. J Biol Chem 276: 34182-34188.
26. Clayton A, Steadman R, Williams JD (1997) Cells isolated from the human cortical interstitium resemble myofibroblasts and bind neutrophils in an ICAM-1-dependent manner. J Am Soc Nephrol 8: 604-615.
27. Dudas J, Mansuroglu T, Batusic D, Saile B, Ramadori G (2007) Thy-1 is an in vivo and in vitro marker of liver myofibroblasts. Cell Tissue Res 329: 503-514.
28. Austyn JM, Gordon S (1981) F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 11: 805-815.
29. Ricardo SD, van Goor H, Eddy AA (2008) Macrophage diversity in renal injury and repair. J Clin Invest 118: 3522-3530. doi: 10.1172/JCI36150
30. Mantovani A, Sica A, Locati M (2005) Macrophage polarization comes of age. Immunity 23: 344-346.
31. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
32. Kushiyama T, Oda T, Yamada M, Higashi K, Yamamoto K, et al. (2011) Alteration in the phenotype of macrophages in the repair of renal interstitial fibrosis in mice. Nephrology (Carlton) 16: 522-535.
33. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, et al. (2003) Identification of neutrophil gelatinaseassociated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534-2543.
34. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, et al. (1998) Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273: 4135-4142.
35. Nabity MB, Lees GE, Cianciolo R, Boggess MM, Steiner JM, et al. (2012) Urinary biomarkers of renal disease in dogs with X-linked hereditary nephropathy. J Vet Intern Med 26: 282-293. doi: 10.1111/j. 1939-1676.2012.00891.x
36. Wang Y, Harris DC (2011) Macrophages in renal disease. J Am Soc Nephrol 22: 21-27. doi: 10.1681/ASN.2010030269
37. Lee S, Huen S, Nishio H, Nishio S, Lee HK, et al. (2011) Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 22: 317-326. doi: 10.1681/ASN.2009060615
38. Lin SL, Castano AP, Nowlin BT, Lupher ML Jr., Duffield JS (2009) Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 183: 6733-6743. doi: 10.4049/jimmunol.0901473
39. Wu X, Schulte BC, Zhou Y, Haribhai D, Mackinnon AC, et al. (2014) Depletion of M2-like tumor-Associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol 134: 2814-2822. doi: 10.1038/jid.2014.206
40. Jedlicka J, Soleiman A, Draganovici D, Mandelbaum J, Ziegler U, et al. (2010) Interstitial inflammation in Alport syndrome. Hum Pathol 41: 582-593. doi: 10.1016/j.humpath.2009.08.024
41. Lebleu VS, Sugimoto H, Miller CA, Gattone VH 2nd, Kalluri R (2008) Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab Invest 88: 284-292. doi: 10.1038/labinvest.3700715
42. Koepke ML, Weber M, Schulze-Lohoff E, Beirowski B, Segerer S, et al. (2007) Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant 22: 1062-1069.
43. Gross O, Perin L, Deltas C (2014) Alport syndrome from bench to bedside: The potential of current treatment beyond RAAS blockade and the horizon of future therapies. Nephrol Dial Transplant 29 Suppl 4: iv124-130. doi: 10.1093/ndt/gfu028